Drug intelligence / Profile preview

KLF2 siRNA

Development stage
Preclinical
Lead developer
Dharmacon
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

KLF2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Krϋppel-like factor 2 (KLF2), a flow-sensitive transcription factor. In vascular biology research, it is used to investigate the role of KLF2 in regulating endothelial barrier function, junctional stability, and cellular alignment in response to laminar shear stress. By targeting and degrading KLF2 mRNA through RNA interference, this reagent allows researchers to observe the physiological consequences of KLF2 deficiency, such as increased intracellular gaps and impaired barrier integrity in pulmonary artery endothelial cells. It is primarily utilized as a research tool to understand the mechanisms underlying conditions like high cardiac output pulmonary hypertension.

Other names
KLF2 small interfering RNAKLF-2 small interfering RNAKLF 2 small interfering RNAKruppel-like factor 2 siRNA
02

Targets

KLF2 (Krüppel-like factor 2)

Beyond the preview

Go deeper on KLF2 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLF2 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call